Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Myeloid Malignancies
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: After completion of Safety Run-in cohorts and identification of the RP2D for the specific cohorts, participants will be enrolled to the corresponding Phase 2 cohorts.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study consists of 3 safety run-in cohorts; Safety Run-in Cohort 1 (Mag + Ven + Aza) Safety Run-in Cohort 2 (Mag + MEC) Safety Run-in Cohort 3 (Mag + CC-486) Participants will receive treatment at the assigned dose level for at least 4 cycles in the Safety Run-in cohorts, after which they may co...
This study consists of 3 safety run-in cohorts; Safety Run-in Cohort 1 (Mag + Ven + Aza) Safety Run-in Cohort 2 (Mag + MEC) Safety Run-in Cohort 3 (Mag + CC-486) Participants will receive treatment at the assigned dose level for at least 4 cycles in the Safety Run-in cohorts, after which they may continue at the assigned dose level or switch to the RP2D upon agreement between the investigator and the sponsor. After completion of each safety run-in cohort and identification of the RP2D for that cohort, participants will be enrolled into the corresponding Phase 2 cohorts; Phase 2 Cohort 1 (Mag + Ven + Aza) Phase 2 Cohort 2 (Mag + MEC) Phase 2 Cohort 3 (Mag + CC-486) Cycle length is 28 days for both the Safety Run-in and Phase 2 cohorts.
Tracking Information
- NCT #
- NCT04778410
- Collaborators
- Not Provided
- Investigators
- Study Director: Gilead Study Director Gilead Sciences
Get Well Soon